Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT06625307 | A Research Study on the Effects of NNC0537-1482 in Healthy Individuals When Injected Under the Skin | PHASE1 | COMPLETED | 31 | — | — | Oct 3, 2024 | May 4, 2025 | Jun 25, 2025 | 1 | Netherlands |
Number of events.
Number of events.
Number of events.
| Arm | Type | Description |
|---|---|---|
| NNC0537-1482 Dose level 1 | EXPERIMENTAL | Participants will be administered a single dose of dose level 1 of NNC0537-1482 subcutaneously. |
| NNC0537-1482 Dose level 2 | EXPERIMENTAL | Participants will be administered a single dose of dose level 2 of NNC0537-1482 subcutaneously. |
| NNC0537-1482 Dose level 3 | EXPERIMENTAL | Participants will be administered a single dose of dose level 3 of NNC0537-1482 subcutaneously. |
| NNC0537-1482 Dose level 4 | EXPERIMENTAL | Participants will be administered a single dose of dose level 4 of NNC0537-1482 subcutaneously. |
| NNC0537-1482 Dose level 5 | EXPERIMENTAL | Participants will be administered a single dose of dose level 5 of NNC0537-1482 subcutaneously. |
| NNC0537-1482 Dose level 6 | EXPERIMENTAL | Participants will be administered a single dose of dose level 6 of NNC0537-1482 subcutaneously. |
| Placebo | PLACEBO_COMPARATOR | Participants will be administered a single dose of Placebo matched to NNC0537-1482 subcutaneously |
| Name | Type | Description |
|---|---|---|
| NNC0537-1482 | DRUG | Administered via subcutaneous route |
| Placebo | DRUG | Administered via subcutaneous route |
Inclusion Criteria: * Male or postmenopausal female. * Age 22-55 years (both inclusive) at the time of signing the informed consent. * Body Mass Index (BMI) between 18.5 and 30.0 kilogram/meter per square (kg/m\^2) (both inclusive) at screening. * Considered eligible and generally healthy based on ...